Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Vesalius Cardiovascular Reaches a New and Advanced Pre-Clinical Milestone

Vesalius Cardiovascular Inc. (VCI), a Canadian MedTech company developing a Transfemoral Mitral Valve Repair (TMVr) solution, announced today the achievement of a new pre-clinical milestone with its 180-day chronic animal study.

Vesalius Cardiovascular notes the predetermined endpoints of the study were the feasibility and durability of VCI’s papillary muscle anchoring device. Both endpoints were confirmed at the 180-day mark.

Dr. Peter Skarsgard, veteran cardiac surgeon and VCI’s Chief Scientific Officer, commented, “Our catheter-based solution can reproduce surgical mitral valve repair, but without the burden of the operation. We designed and developed a TMVr solution that is based upon proven surgical principles and material. Our concept is derived from the clinically proven chordal replacement technique and uses a papillary muscle anchoring device. In this specific study, our anchors replaced the native chordae attachments to the papillary muscles and are successfully carrying the load of the functioning anterior leaflet, preventing mitral regurgitation. This is proof that our anchoring device can durably reproduce a surgically placed suture in the papillary muscle.”

Echocardiographic images were obtained during the procedure and, subsequently, at seven, 30 and 180 days by Dr. Christopher Durkin, a cardiovascular anaesthesiologist, echocardiographer, and VCI’s clinical advisor, who added, “Imaging at 180 days confirms the absence of mitral regurgitation and, more importantly, the absence of anchor migration, proving that VCI’s anchors are acting exactly like the native chordae attachments.”

“This milestone is a major step in our development plan,” added Vincent Ledoux, VCI’s Chief Operating Officer. “Despite the pandemic, we were able to maintain our timeline intact thanks to the firepower of eight experienced biomedical engineers, continuously translating decades of cardiovascular expertise into a TMVr solution. We have transformed a complex operation (open heart) that uses a simple repair tool (sutures) into a sophisticated device with a simple delivery procedure.”

Dr. Jacqueline Saw, structural interventional cardiologist and VCI’s clinical advisor, noted, “The VCI solution is comprehensive mitral valve repair, delivered with a catheter. The device design leads to remarkable simplification and standardization of the delivery procedure, from case to case, with no compromise on effectiveness. This optimizes user needs, for both patient and provider.”

“Our unique solution is monopolistic in that we can treat the full spectrum of Degenerative Mitral Regurgitation, whether simple or complex, with or without annular dilation, using adapted chordal replacement and annuloplasty concepts in one device. No other solution can offer that,” said Dr. Skarsgard, adding, “Simply said, in any size valve, our device can treat any expression of degenerative disease – it is a one-size-fits-all solution.”

To date, VCI has raised $5 million from a solid base of investors and early believers and is expecting to reach the First-In-Human stage by mid-2022.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy